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Background: Mouse mammary tumor virus (MMTV) is a complex, milk-born betaretrovirus, which preferentially
infects dendritic cells (DC) in the gastrointestinal tract and then spreads to T and B lymphocytes and finally to the
mammary gland. It is not clear how the prototypic betaretrovirus infects mucosal DCs and naïve lymphocytes as
these cells are considered to be non-proliferative. Studies of MMTV biology have been hampered by the difficulty
of obtaining sufficient virus/vector titers after transfection of a molecular clone in cultured cells. To surmount
this barrier we developed a novel MMTV-based vector system with a split genome design containing potent
posttranscriptional regulatory functions.
Results: Using this system, vector particles were produced to markedly greater titers (>1000-fold) than those
obtained previously. The titers (>106 transduction units /ml) were comparable to those achieved with lentiviral or
gammaretroviral vectors. Importantly, the vector transduced the enhanced green fluorescence protein gene into the
chromosomes of non-dividing cells, such as cells arrested at the G2/M phase of the cell cycle and unstimulated
hematopoietic progenitor cells, at an efficiency similar to that obtained with the HIV-1-based vector. In contrast to
HIV-1, MMTV transductions were not affected by knocking down the expression of a factor involved in nuclear import
of the HIV-1 pre-integration complexes, TNPO3. In contrast to HIV-1, the MMTV-based vector did not preferentially
integrate in transcription units. Additionally, no preference for integration near transcription start sites, the regions
preferentially targeted by gammaretroviral vectors, was observed. The vector derived from MMTV exhibits a random
integration pattern.
Conclusions: Overall, the betaretroviral vector system should facilitate molecular virology studies of the prototypic
betaretrovirus as well as studies attempting to elucidate fundamental cellular processes such as nuclear import
pathways. Random integration in cycling and non-cycling cells may be applicable in unbiased gene delivery.
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Mouse mammary tumor virus (MMTV) is a milk-born
betaretrovirus associated with mammary adenocarcinomas
in mice [1]. Unlike other retroviruses, MMTV displays a
high degree of tissue specificity in vivo. Expression of
MMTV is mainly limited to the mammary gland, where
the virus replicates extensively, particularly during lac-
tation when the levels of glucocorticoid hormone rise.
Replication of MMTV during lactation ensures efficient
transmission of the virus from mother to offspring. In
the infected animals, the virus preferentially infects
dendritic cells, naïve B and T lymphocytes and is subse-
quently transmitted to the mammary gland where it
ultimately infects mammary epithelial cells [2,3]. The
cell types targeted at the initial stages of infection are
reminiscent of the cell types infected by the prototypic
lentivirus, human immunodeficiency virus type 1 (HIV-1).
Macrophages and dendritic cells at the mucosal surface
are the first immune cells targeted by HIV-1. Although
these cells are terminally differentiated and as such non-
proliferative, they are efficiently productively infected by
HIV-1. MMTV, like HIV-1, initiates infection of the host
organism by infecting the mucosal dendritic cells. Never-
theless, the possibility that it is capable of infecting non-
proliferating cells has not been experimentally tested.
Studies of the prototypic betaretrovirus have been ham-
pered due to a low virus production from natural virus
producers (such as cell lines derived from mammary tu-
mors), as well as insufficient MMTV-based vector produc-
tion after transfection of molecular clones into cultured
cells. This is a result of the complex regulation of virus gene
expression, which is dependent not only on the glucocortic-
oid hormone, stimulating the MMTV promoter, but also
on a functional analogue of the HIV-1 Rev protein, Rem.
[4-6]. Rem, like Rev, binds to its responsive element on viral
RNA, the ribonucleoprotein complex is then recognized by
a cellular factor CRM1, recruited to the nuclear pore com-
plex and exported to the cytoplasm [7-10].
Understanding of the regulation of gene expression en-
abled us to design and construct a novel MMTV-based
vector system analogous to the third generation lenti-
viral vectors. Replication-incompetent vectors, pseudo-
typed with the G protein of the vesicular stomatitis
virus (VSV-G), were produced to ~1000 fold greater
titers than those obtained previously. The high titer
vector production allowed us to address the question of
whether MMTV is capable of infecting non-mitotic
cells such as γ-irradiated cell lines and un-stimulated
hematopoietic stem cells. Here we provide the first
direct evidence that MMTV-based vector transduces
non-proliferating cells, thereby explaining its ability to
infect cells such as mucosal dendritic cells and naïve B
lymphocytes. The prototypic betaretrovirus can thus be
added to the small group of retroviruses that are capableof infecting cells independently of cell cycle progression.
In contrast to other retroviruses, however, the MMTV
pre-integration complex does not seem to require a cel-
lular factor TNPO3 for nuclear import. Additionally,
the high titer MMTV-based vector exhibits, regardless
of whether cycling or non-cycling cells were transduced,
a random integration pattern reminiscent of the un-
biased integration profile previously demonstrated for
the wild type MMTV [11]. This property distinguishes
MMTV-based vector from other vectors derived from
gammaretroviruses and lentiviruses, which preferentially
integrate near transcriptional start sites and within genes,
respectively [12,13].
Results
Description of MMTV-based vector with a split genome
design
To overcome the difficulty to produce MMTV vector
to high titers that would enable in-depth studies of
molecular virology of the prototypic betaretrovirus, we
developed a novel betaretrovirus vector production sys-
tem. Analogously to the third generation of lentiviral
vector system, four-plasmids were used to generate
MMTV-derived retroviral vector particles by transient
transfection [14]. The conditional packaging construct,
pCMVgpRRE17, contains the human cytomegalovirus
immediate early promoter (CMV), which drives the ex-
pression of the structural and enzymatic components
of MMTV. The plasmid contains the Mtv-1 sequences
upstream of the EcoRI site in pol and a sequence derived
from the exogenous virus from GR mice [MMTV(GR)]
downstream of this site (Figure 1A, the integrase-coding
portion of pol is derived from the MMTV(GR)). The pack-
aging signal (ψ) was deleted from the 5′leader region [15]
and the plasmid is defective for the production of the viral
envelope protein. A bovine growth hormone polyadenyla-
tion signal (BGH pA), cloned in place of the 3′LTR, serves
as transcriptional termination signal. Analogously to other
complex retroviruses, efficient expression of the MMTV
gag and pol genes requires the presence of a cis-acting
posttranscriptional regulatory element, which allows bind-
ing of a viral RNA export factor and thereby facilitates the
accumulation of RNA in the cytoplasm [7,8]. Therefore,
the HIV-1 Rev responsive element (RRE) was inserted
downstream of the pol gene and the resulting plasmid was
cotransfected with a Rev expression vector into HEK293T
cells (Figure 1A) [14]. To broaden vector’s tropism and
enhance its stability and titer, we used a plasmid encod-
ing a heterologous envelope protein, derived from ves-
icular stomatitis virus (VSV-G), for pseudotyping the
particles generated by pCMVgpRRE17 [16,17]. A
chimeric transfer vector, pRRpCeGFPWPRE25, derived
from the MMTV molecular clone pGR102 [18] contains
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Figure 1 (See legend on next page.)
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Figure 1 MMTV-based vector system. (A) Schematic representation of the MMTV provirus and the four-plasmid expression system used for
generating MMTV-based vectors. For the MMTV provirus the regions encoding structural, enzymatic and accessory proteins are shown. The splice
donor (SD) and acceptor (SA) sites with their nucleotide coordinates, the long terminal repeat (LTR), the Rem responsive element (RmRE) and the
packaging signal are also indicated. In the transfer vector, pRRpCeGFPWPRE25, the truncated gag gene is followed by the Rev responsive element
(RRE) from HIV-1 and the internal CMV promoter that drives the expression of enhanced green fluorescent protein (EGFP). Woodchuck hepatitis
virus posttranscriptional element (WPRE) upstream of the 3′ LTR is also indicated. In the packaging construct pCMgpRRE17, the restriction sites
used for the construction of this chimera, SD, SA, RRE and the beta globin polyadenylation signal (βg pA) are shown. The Rev-encoding plasmid
(pRSV-Rev) and the VSV-G envelope protein-encoding plasmid (pHCMV-G) have been previously described [14,22]. (B) and (C) Infectious titers
of VSV-G-pseudotyped vectors (transduction units [TU]/ ml) determined by flow cytometric analysis on transduced HeLa cells three days post
transduction using un-concentrated (B) or concentrated (C) supernatant from transfected 293 T cells. The mean values from three infection
replicates are shown, together with the standard deviations (SD). (D) Time-course analysis of EGFP positivity after single exposure of HeLa cells to
the MMTV- or HIV-1-based vectors. The cells were analysed by FACS at various time points (days 3-48) after transduction. Transductions were performed
in triplicate. All values are means ± SD. The nucleotide coordinates are based on the prototypic MMTV strain BR6 (GenBank Acc. no.15122).
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reverse transcription and integration into the host
genome. The 5′ leader sequence [containing the primer
binding site (PBS)], ~ 400 base pairs of gag, the 3′end of
env, [carrying the polypurine tract sequence (ppt)] and the
3′LTR were included in the pRRpCeGFPWPRE25 vector.
To ensure efficient and hormone-independent transcrip-
tion, the U3 region of the Rous sarcoma virus (RSV) LTR,
containing the enhancer/promoter, was substituted for the
U3 region of the MMTV 5′LTR. The substitution was
made in such a manner as to preserve the transcription
initiation site of MMTV. The posttranscriptional regula-
tory element of woodchuck hepatitis virus (WPRE) and
RRE sequences were inserted into the transducing vector
to stabilize RNA and allow efficient nuclear export of full-
length vector transcripts in the presence of the regulatory
protein expressed in trans [19,20]. The Rem responsive
element (RmRE), which spans the env-U3 junction, is also
present in the construct containing the complete 3′LTR
[9,21]. The enhanced green fluorescent protein (EGFP)
gene, driven by the CMV promoter, was used as a reporter
(Figure 1A).
High-titer vector production upon co-transfection of the
four-plasmids into HEK 293 T cells
Replication-defective MMTV-based vector particles were
generated by transient co-transfection of the four plas-
mids into HEK293T cells. As controls, third generation
HIV-1-derived packaging and transducing vectors and
stable MLV vector producers were used [14,23,24]. VSV-G
pseudotyped vector particles from various transfectants
were filtered and assayed for transduction efficiency on
HeLa cells. MMTV-based EGFP-carrying vectors yielded
titers of 1.3 × 106 ± 3.5 × 105 transduction units (TU)
per milliliter (ml) of unconcentrated supernatant and
mean fluorescence intensity (MFI) of 560 ± 157 (Additional
file 1: Figure S1). This titer was comparable to that obtained
with both the HIV-1-based vector produced by the same
method (4.6 × 106 ± 2.0 × 106 TU/ml; MFI = 1585 ± 275)
and the stably produced MLV-based vector (2.8 × 106 ±9.2 × 105 TU/ml; MFI = 324 ± 26) (Figure 1B). Infectious
MMTV vector titers above 1 × 108 TU/ml were obtained
after concentration by ultracentrifugation (Figure 1C). Fur-
thermore, the pseudobetaretrovirus vector-transduced cells
remained EGFP positive for at least seven weeks after trans-
duction, suggesting that the vector was stably integrated
into the host genome (Figure 1D).
SIN design of MMTV-based vector does not decrease
vector titer
To reduce genotoxic potential of the MMTV vector har-
boring a potent enhancer element and to avoid promoter
interference, we also generated two self-inactivating (SIN)
variants of the transfer vector by leaving out most of the
1.2 kb 3′ U3 region (Figure 1A, inner panel). In both SIN
variants the attachment site, required for the interaction
with the integrase, was maintained (~50 bp). In the first de-
letion construct (pRRpCeGFPWPRE25_1293), the com-
plete promoter/enhancer region, including the TATA box,
was removed, leaving only the core elements of pre-mRNA
processing signals (cleavage and polyadenylation specificity
factor [CPSF] and cleavage stimulating factor [CstF] re-
cognition motifs). The second SIN vector (pRRpCeGFPW
PRE25_1218) contained, in addition to the CPSF and the
CstF recognition motifs, additional cis-acting elements
including the U-rich region and CF Im recognition motif,
involved in the regulation of mRNA polyadenylation
[25,26]. When the SIN vector with the longer deletion,
pRRpCeGFPWPRE25_1293, was used for transduction,
the titers determined were approximately 20% of those
obtained with the parental vector carrying an intact 3′
LTR. This vector also exhibited a moderately decreased
MFI when compared to the parental vector. In contrast,
the vector pRRpCeGFPWPRE25_1218, yielded titers
slightly greater than the parental vector (Additional file 1:
Figure S2A and S2B). As expected, absence of the enhan-
cer abolished hormone responsiveness and no increase in
the vector RNA levels could be detected in transduced
cells upon dexamethasone stimulation (Additional file 1:
Figure S3).
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cycle
In contrast to HIV-1 and other lentiviruses, most oncor-
etroviruses require cell division to enter the host cell
genome and integrate viral DNA in the chromosomes
[27-33]. Little is known about MMTV’s ability to infect
non-dividing cells. In vivo, the milk-transmitted MMTV
crosses the gut and preferentially infects naïve B lym-
phocytes and dendritic cells in the gastrointestinal tract,
which are generally non-proliferative [3,34]. This sug-
gests that MMTV has the capacity to infect non-cycling
cells.
To assess whether MMTV is able to infect non-
dividing cells we used the high-titer betaretrovirus vec-
tor and we first assessed its ability to transduce cells
arrested in the cell cycle by γ-irradiation. HEK 293 cells
exposed to 50 Gy from a linear accelerator source were
arrested in the G2/M phase (Figure 2A). The irradiated
cells and their non-irradiated counterparts were exposed
to MMTV(SIN) vector 24 h after the treatment. Parallel
transductions with HIV-1 and MLV vectors served as
positive and negative controls, respectively. As expected,
transduction of G2/M-arrested cells with MLV vector
was reduced to 11.1 ± 3.5% of the level detected in pro-
liferating cells. In contrast, the HIV-1-based vector effi-
ciently transduced non-proliferating cells, giving rise to
titers of 92.4 ± 31.6% of those detected on proliferating
cells (Figure 2B and C; 3dpi). Interestingly, the pheno-
type of MMTV(SIN) was similar to that obtained with
the HIV-1 vector. Only a moderate reduction in infectious
titers was detected on arrested cells relative to cycling cells
(93.2 ± 19.2%) (Figure 2B and C; 3dpi). Importantly, heat
treatment of vectors abolished transduction and the pres-
ence of 3′-azido-3′-deoxythymidine (AZT) profoundly
reduced the number of EGFP-positive cells (Figure 2C).
Together, these results indicated that the presence of
EGFP cannot be attributed to pseudotransduction events
resulting from a passive transfer of EGFP protein or plas-
mid DNA.
To ascertain whether the wild-type virus can also infect
non-proliferating cells, we tested the infectivity of the GR
strain of MMTV [MMTV(GR)] on the γ-irradiated cells.
As shown in Figure 2D, an MMTV(GR)-specific PCR
product was detected in G2/M-arrested cells infected with
the virus but not in cells infected with a heat-treated virus
or in cells cultured in the presence of AZT. Collectively,
the results indicate that both the wild-type virus and the
MMTV-derived vector are able to infect non-proliferating
cells.
Transduction of hematopoietic stem cells
As the MMTV(SIN) vector transduces G2/M-arrested
cells, we next investigated whether the vector can also
transduce quiescent hematopoietic stem cells (HSC).These cells, which represent attractive targets for gene
therapy applications, do not divide unless stimulated with
cytokines. Bone marrow-derived human hematopoietic
stem cells (CD34+) (Figure 2E) were cultured in StemSpan
serum-free medium (StemCell Technologies) either with-
out supplements or supplemented with a cocktail of
early-acting cytokines (rhIL-6, rhSCF, rhFlt-3 ligand and
rhTPO). The primary CD34+ cells were seeded at a con-
centration of 1.5 × 106 cells/ml and MMTV(SIN) vector
or HIV-1 vector (1.5 × 107 TU/ml) was applied. A direct
comparison of the betaretroviral and lentiviral vectors,
performed by UV microscopy and flow cytometry on day
16 post-transduction, showed that the transduction rates
of the two vectors did not differ markedly. As expected,
the HIV-1-based vector transduced the CD34+ cells re-
gardless of whether the cells were stimulated with cyto-
kines. Only a slightly reduced transduction rate was
detected when the cells were grown in the absence of cy-
tokines. Importantly, the MMTV-based vectors also trans-
duced the human primary HSC grown without cytokines
and the transduction efficiency of the betaretrovirus-based
vector was comparable to that of the lentivirus-derived
control vector (Figure 2F and G).
Similar results were obtained when the performance of
the HIV-1 and MMTV vectors was directly compared in
cultured lineage negative HSC derived from the murine
bone marrow. Both vectors transduced the lineage nega-
tive cells cultured in the absence or the presence of the
cytokine cocktail comprising of rmIL-3, rmSCF, rmFlt-3
ligand and rmTPO. Although the transduction rate of
the MMTV vector was reduced in the absence of cyto-
kines (by about three-fold), under these conditions the
MMTV vector was more efficient than the lentiviral vector
(Additional file 1: Figure S4). These results demonstrate
the potency of the newly designed betaretroviral split
packaging system for transducing human and murine
HSC in the absence of cell division.
TNPO3 depletion does not lead to a reduction of MMTV
infectivity
Infection of non-dividing cells, which have an intact nu-
clear membrane, requires the active import of a viral
nucleoprotein complex [pre-integration complex (PIC)]
through the nuclear membrane pores. The mechanisms
exploited by lentiviruses to infect non-cycling cells have
been a subject of debate. It appears that lentiviruses use
several nuclear import pathways to gain access to the host
chromosomes. One of the pathways includes a member
of the nuclear pore complex Nup358/RanBP2 and a
member of the karyopherin β superfamily of proteins,
TNPO3/Transportin 3 [35-37]. These proteins associate
with the HIV-1 capsid (CA) protein, which, at least to
some extent, remains in the pre-integration complex


































































































































Figure 2 (See legend on next page.)




























Figure 3 Effect of TNPO3 knockdown on transduction efficiency
of MMTV and HIV-1 vectors. (A) Hela cells transfected with the
TNPO3-specific or non-silencing siRNA were transduced with HIV-1
and MMTV vectors 48 h after transfection. At 48 h post transduction
cells were harvested and the percentage of EGFP-positive cells was
determined by flow cytometry. Transduction efficiency in TNPO3-specific
siRNA-treated cells relative to control siRNA-treated cells is shown. Results
represent mean values ± standard deviation of three independent
experiments. (B) The expression levels of TNPO3 at the time
of transduction (48 h post transfection) were determined by
immunoblotting with an anti-TNPO3-specific antibody. Equivalent
loading and blotting was confirmed by membrane re-probing
using an anti-actin-specific antibody.
(See figure on previous page.)
Figure 2 Transduction of non-dividing cells. (A) 293 cells were exposed to ionizing radiation (50 Gy) and 24 h later (at the time of transduction)
stained with propidium iodide and analysed by flow cytometry. Non-irradiated cells used as a control showed a well defined G1 peak. Exposure to
radiation resulted in an accumulation of virtually all cells in the G2/M stage of the cell cycle. (B) The irradiated and non-irradiated cells were transduced
with MMTV-based vector. As positive and negative controls, for transduction of non-dividing cells, vectors derived from HIV-1 and MLV were used.
The transduced cells were analysed by UV microscopy and FACS analysis 3 days post transduction. (C) Viral titers expressed as percentages of titers
obtained on dividing cells (black columns). The cells of one set of transduced irradiated cells were exposed to AZT (10 μM, white columns). Another
control is represented by a heat-treated vector (65°C, 10 min, grey columns). For the controls, the titer is given as a percentage of titers observed on
untreated cells. Error bars indicate standard deviation from the mean of three independent transduction experiments. (D) The irradiated cells were
infected either with MMTV(GR) or the same virus treated with heat (65°C, 10 min). The infected cells were cultured in the absence or presence of AZT
(GR + AZT) for 7 days. MMTV-specific PCR was used to detect the presence of MMTV provirus in the infected cells. GAPDH-specific PCR with equivalent
DNA amounts was used as control. (E) The purity of bone marrow-derived CD34+ preparations was verified by flow cytometry using an anti-CD34-PE
antibody. (F)+ (G) The hematopoietic progenitor cells (1 × 106 cell/ml) transduced with the MMTV-or HIV-based vector (1 × 107 TU/ml) were
cultured in the presence or absence of growth factors for 16 days and analysed by UV microscopy and FACS. Representative figures of microscopic
(G) and flow cytometric (F) analysis of transduced cells are shown.
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dependent on TNPO3, we knocked down the expres-
sion of the karyopherin in HeLa cells and followed the
transduction levels in these cells. As expected the de-
pletion of TNPO3 resulted in a reduction of the HIV-1
vector infectivity (Figure 3A and B). In contrast, trans-
duction levels of the MMTV vector were not affected
by the siRNA treatment (Figure 3A). Thus, the results
suggest that MMTV exploits a nuclear import pathway that
is distinct from the TNPO3/RanBP2-dependent pathway.
Neutral integration of MMTV-based vector
To investigate the genomic distribution of the integrated
vectors, we mapped the location of integration sites in
the transduced HeLa cells [MMTV and MMTV(SIN)]
and γ-irradiated 293 cells [MMTV(SIN)arrest] (3 dpt) by a
ligation-mediated polymerase chain reaction (LM-PCR)
followed by 454-pyrosequencing. After a stringent quality
control and dereplication, 254 (MMTV), 585 [MMTV
(SIN)] and 671 [MMTV(SIN)arrest] unique integration
sites unambiguously mapped to the human genome draft
hg18. As a first step to analyze the determined integration
sites we assessed the frequency of integrations within the
Reference Sequence genes (RefSeq, National Center for
Biotechnology Information) and regions proximal to
transcription start sites (TSS), the features displaying
marked integration-targeting differences among retrovi-
ruses [12,13,39-42]. The random, computationally gener-
ated, integration frequencies (n = 100 000) and previously
identified integration sites for HIV-1 and MLV vectors
[12,13,39] were used as controls. The integration frequen-
cies of the MMTV vectors in the proximity (±2 kb) of TSS
was not increased relative to random control [MMTV
(SIN) = 3.7%, [Χ2, P = 0.29]; MMTV= 2.6%, [Χ2, P = 0.73];
MMTV(SIN)arrest = 2.8%; [Χ2, P = 0.81]; random= 3.0%]
(Figure 4A). This strongly contrasted with the integration
pattern of MLV vector, which preferentially targets TSS
(MLV = 15.7%, [Χ2, P < 0.0001]) [12].A significantly lower MMTV vector integration frequen-
cies relative to HIV-1 and MLV integration frequencies
were observed when targeting within RefSeqs was analyzed.
In contrast to HIV-1 and MLV, MMTV vectors integrated
in RefSeq genes with the frequency indistinguishable
from that of random placements [MMTV(SIN) (43.6%,
[Χ2, P = 0.65]); MMTV (44.1%, [Χ2, P = 0.58]; MMTV
(SIN) arrest = 43.9%, [Χ2, P = 0.56]; random = 40.3%)
(Figure 4B and C). Similar picture was obtained when
we analyzed the distribution of integration sites as a
function of gene density. Significanty less MMTV inte-
grants than HIV-1 and MLV integrants were found in
Figure 4 Distribution of integration sites. (A) Distribution of MMTV (n = 254), MMTV(SIN) (n = 585), MMTV(SIN)arrest (n = 671), HIV-1 (n = 3246)
and MLV (n = 885) integration sites within a 20 kb window centered on Transcription Start Sites (TSS). The vertical dashed line shows TSS (0 kb).
The integration sites were binned to 1 kb or 3 kb sequence windows and plotted as the percentage of all integrations per kb. The distribution of
a set of 100 000 computationally-generated random integration sites is represented by the dotted horizontal line. (B) Integration site preferences
of retroviral vectors relative to random control. Tile color code indicates whether the vector integrations departure (red) or not (green) from random
control. The numbers represent the Chi-square p-values. P < 0.01 was considered as a significant difference from random dataset. (C) Distribution of
integration sites within RefSeq genes (hg 18). Differences between virus integrations and random control were analyzed by a Chi-square test.
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file 2: Figure S7). The MMTV vectors also integrated less
frequently within cancer-related genes (Additional file 2:
Figure S7, Additional file 3: Tables S1 and Additional
file 4: Table S2). Further, analysis of integration frequency
relative to a collection of other genomic features showed
that MMTV vectors do not specifically target any of these
regions (Figure 4B, Additional file 2: Figure S5 and S6).
The only significant difference between random dataset
and MMTV-vector integration sites [MMTV; MMTV
(SIN)arrest] was detected for integrants mapped to the
short interspersed nuclear elements (SINEs) (Figure 4B
and Additional file 2: Figure S6).Together, these results showed that MMTV vectors,
like the wild type virus [11], do not preferentially target
TSS, genes and most of the other genomic features ana-
lyzed. The semi-random integration phenotype strongly
contrasts with the phenotype of γ-retroviruses and
lentiviruses, which preferentially target TSS and genes,
respectively.
Discussion
Mouse mammary tumor virus (MMTV) has served as an
important model in breast cancer research. The gluco-
corticoid hormone-responsive promoter has been exploited
for conditional gene expression in cell culture as well as for
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gland. However, development of an efficient MMTV-
derived vector has been hampered by the low vector titers
obtained after transfection into cultured cells [4-6]. The
failure to produce a high titer vector could result from low
cytoplasmic levels of vector RNA attributable to insufficient
expression of a functional homologue of the HIV-1 Rev
protein, termed Rem. Rem interacts with a Rem-responsive
element (RmRE) in viral RNAs and facilitates the cyto-
plamic accumulation of viral transcripts, which are
subsequently either translated into the structural and
enzymatic components of the virus or serve as the viral
genomic RNA [9,21]. To circumvent the difficulty with
low vector titers we produced MMTV-based transdu-
cing particles in HEK293T cells using a four-plasmid
expression system. The first two plasmids, packaging
construct and transfer vector, contain an element from
HIV-1 analogous to RmRE (RRE), which in the presence
of HIV-1 Rev (supplied in trans from the third plasmid)
ensures efficient nuclear export of vector transcripts in
the human kidney cell line (Rev/RRE was used because
Rem/RmRE functioned less efficiently in these cells). The
infectious vector titer obtained with this production sys-
tem (>106 TU/ml) markedly exceeded (~1000-fold) the
titers previously reported for MMTV-based vectors [4,5]
and was comparable to titers obtained with the third gen-
eration of lentivirus-based vector systems and stably pro-
duced MLV-derived vectors [14,24]. The MMTV-derived
transducing particles could be pseudotyped with VSV-G
envelope protein and the pseudoparticles were resistant to
high speed centrifugation, allowing further concentration
to > 108 TU/ml.
Comparison of integration specificities of MMTV-based
vectors with other integrating vectors showed that the
high titer MMTV vector does not have a preference for
integrating within genes or near promoters, the loci
targeted by HIV-1 and MLV vectors, respectively. In con-
trast, irrespective of whether the complete U3 region is
maintained, the vector integrates with a specificity indis-
tinguishable from random integration placements. The
random integration pattern is consistent with the reported
integration profile of wild-type MMTV [11] and suggests
that the MMTV integrase (IN) does not interact with the
LEDGF/p75 transcription factor, which is responsible for
targeting HIV-1 into active genes [43]. It remains to be
elucidated whether the MMTV IN associates with another
cellular factor(s), which leads to the random integration
profile, or whether it is itself the principal determinant of
integration site selection with low-specificity binding to
host DNA. Regardless of the mechanism, our results sug-
gest that MMTV-based vectors may be suitable for appli-
cations in gene therapy, as they would decrease the risk of
mutating and/or activating cellular genes including proto-
oncogenes and tumor suppressor genes. Generation of selfinactivating variants of retroviral vectors (SIN), repre-
sent another step towards increased biosafety of viral
vectors. We also generated a self inactivating (SIN) vari-
ant that was as infectious as the non-SIN vector. The
SIN vector lacks the potent enhancer element, reducing
the risk of enhancer-mediated activation of neighboring
genes. Whether the use of the randomly integrating
betaretrovirus-based SIN vectors in vivo would represent
a significant safety improvement over other retroviral
vectors remains to be elucidated. MMTV is transmitted
via the milk and first infects the mucosal dendritic cells
before spreading to T and B lymphocytes in the Peyer’s
patches of the gut [2,3]. MMTV encodes an enzyme
deoxyuridine triphosphate nucleotidohydrolase (dUTPase)
[44]. Although the role of this enzyme in the life cycle of
MMTV is unknown, dUTPases of non-primate lentivi-
ruses are thought to facilitate viral replication in non-
dividing cells. The enzyme limits dUTPs pools in infected
cells and thereby minimizes the misincorporation of ura-
cils into viral DNA [45]. The fact that MMTV encodes
dUTPase and is able to infect dendritic cells, which are
largely non-proliferative, suggests that the virus may
be able to infect cells regardless of cell cycle progres-
sion. Retroviruses differ widely in their requirements
for mitosis for productive infection of host cells. Some
of them are nearly totally dependent on cell cycle pro-
gression (MLV, spleen necrosis virus), while others
show an intermediate phonotype (avian sarcoma virus)
or seem almost completely independent of cell prolif-
eration (lentiviruses) [27-33].
Our novel high-titer MMTV vector production system
enabled us to test whether MMTV is capable of infecting
non-mitotic cells. We found that the MMTV-based vector
transduced cell cycle-arrested cells as well as unstimulated
hematopoietic stem cells with the same efficiency as the
HIV-1-based vector. The results are unlikely to stem from
a leaky cell division of target cells as transduction with the
control cell cycle-dependent MLV-based vector was mark-
edly reduced. Pseudotransduction events can also be ruled
out as EGFP expression was either not detected or was
markedly reduced after transduction with heat-treated
vector or when AZT was added to culture medium. The
vector cDNA was integrated into the host genome as con-
firmed by LM-PCR, which identified 671 unique vector-
host junctions. Thus, we conclude that reporter gene
expression is the result of legitimate, reverse transcrip-
tion-dependent, transduction of non-cycling cells.
The ability of lentiviruses to cross the intact nuclear
membrane of a host cell accounts for their capacity to
efficiently replicate in a mitosis-independent fashion.
The mechanism by which nuclear entry is achieved is
not completely understood.
According to one model the lentiviral capsid protein
(CA) is the major determinant of lentivirus’ ability to
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between cellular factor(s) and lentiviral CA affects virus
uncoating, thereby influencing downstream events such
as nuclear import and integration [35,36,38]. Genome-
wide screens using siRNA technology identified a pleth-
ora of cellular factors that, when depleted from target
cells, reduced the susceptibility of cells to HIV-1 [37,47].
One of them is TNPO3, a karyopherin known to be
involved in the nuclear import of serine/arginine-rich
splicing factors. TNPO3 has been proposed to promote
also the nuclear import of CA-containing PICs via a
pathway that involves a large cyclophilin-related nuclear
pore protein RanBP2 [37]. We found that TNPO3 is
dispensable for infections with MMTV. In contrast to the
HIV-1-based vector, transductions with the MMTV vector
were not reduced when TNPO3 was depleted from target
cells. The result suggests that MMTV uses an alternative,
TNOP3-independent nuclear entry pathway. This pathway
may be the same as that employed by feline immunodefi-
ciency virus (FIV) and the HIV-1 carrying the N47D substi-
tution in CA [35,38]. Recently, it has been demonstrated
that the MMTV CA localizes within the nucleus, further
corroborating the importance of the protein for nuclear
localization of the MMTV PICs [48].
Conclusions
We have demonstrated that MMTV may be used as a
basis for the construction of a high-titer betaretroviral
vector for unbiased delivery of transgenes into host
genomes. Comparable efficiency of both the SIN and
non-SIN constructs in transferring EGFP offers various
possibilities for using MMTV-based vectors. The non-
SIN vector may be used as a hormone-regulated retro-
viral vector, while the SIN vector, lacking the enhancer,
may be used for the relatively safe delivery of genes
into target cells.
The present study describes for the first time several
aspects of the betaretroviral life cycle. We provide evi-
dence explaining MMTV’s natural tropism for infection
of mucosal dendritic cells and naïve B-cells. The pathway
employed to access the nucleus does not involve TNPO3,
a karyopherin used by HIV-1 to reach the host chromo-
somes. The differences in the nuclear entry pathway may
account for the marked differences in integration speci-
ficity detected between the prototypic betaretro- and
lenti-virus. The described vector should facilitate future
betaretrovirology research as well as studies delineating
fundamental cellular processes such as transport across
the nuclear pore complex.
Methods
Cell culture, vector preparations and transductions
HEK293T, HEK 293, HeLa and NMuMG cells were grown
in DMEM supplemented with 10% heat inactivated fetalcalf serum (FCS). HEK 293 T cells were used for produc-
tion of MMTV-and HIV-1-based vectors by transient
transfection as described previously [14]. Briefly, 5 × 106
HEK 293 T cells were seeded in a 10 cm dish the day
before transfection. For the MMTV vector, 5 μg of the
packaging construct (pCMgpRRE17), 6 μg of the vector
pRRpCeGFPWPRE25 or derivatives, 1.1 μg of the VSV-G
Env-encoding plasmid (pHCMV-G) and 3.6 μg of the Rev-
encoding plasmid pLP2 (Invitrogen) were co-transfected
using calcium phosphate transfection protocol. Cell cul-
ture medium was replaced 24 h after transfection with a
serum-reduced medium, Opti-MEM (Life Technologies).
To harvest vector particles, supernatants were collected
24-36 h later, filtered through a 0.45 μm filter and either
stored at−80°C or used for concentration by ultracentri-
fugation (75 000 × g, 2 h, 4°C). The HIV-1 vector was
prepared using the lentiviral packaging (pLP1, Invi-
rogen) and vector (pRRL-cPPT-EGFP; [23]) constructs.
The MLV-based vector was obtained from 2GP19Talf
packaging cells stably transfected with pCEWmCMV
(293Alf-ST-pCEWmCMV; [24]). For transductions, cells
were seeded the day before transduction at a density of
2 × 105 cells per well (6 well plate). Viral vectors were
added to cells together with polybrene (8 μg/ml) and after
3 h replaced with fresh medium.
Human and murine haematopoietic progenitors
Human bone marrow-derived hematopoietic CD34+ stem
cells (Lonza) were plated at a density of 1.5 × 10 6 cells/ml
and cultivated overnight in a serum free StemSpan SFEM
medium (StemCell Technologies) with or without a
cytokine cocktail composed of 100 ng/ml recombinant
human stem cell factor (rhSCF), 20 ng/ml thrombopoietin
(rhTPO), 100 ng/ml rhFlt3-L and 20 ng/ml interleukin 6
(rhIL6) (all from Peprotech). 1.5 × 10 7 transduction units
of MMTV(SIN) or HIV-1 vectors were added to the cells.
After the transduction period (20 h), vector-containing
medium was replaced with the original medium (with or
without cytokines) and cells were cultured for five days.
Then, the cells were resuspended and maintained in the
cytokine-containing medium. UV microscopy and FACS
analysis were performed two weeks after transduction.
Murine bone marrow cells were flushed from the fe-
murs and tibias of eight-weeks-old Balb/c mice and the
lineage negative (Lin−) cells were isolated using Lineage
Cell Depletion kit (Miltenyi Biotech), following the man-
ufacturer’s instructions. The day before transduction, the
Lin− cells were resuspended at a density of 1 × 106 cells/
ml in StemSpan SFEM medium with or without cytokines
consisting of 100 ng/ml recombinant murine stem cell
factor (rmSCF), 100 ng/ml thrombopoietin (rmTPO),
100 ng/ml rmFlt3-L and 20 ng/ml interleukin 3 (rmIL3)
(all from PeproTech). The betaretroviral or lentiviral
vectors concentrated to 1.8 × 107 TU/ml were added to
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the original medium. After five days the original medium
was replaced with the medium containing cytokine cock-
tail and cells were cultured for an additional 10 days.
Irradiation of cells
HEK 293 cells were seeded at a density of 2 × 105 cells/
well (6 well plate) 24 h before exposure to a single radi-
ation dose of 50 Gy using a linear accelerator (Siemens
Primus, Munich, Germany). The γ-irradiated cells were
used for transductions as well as cell cycle analysis by
flow cytometry 24 h after the irradiation.
Construction of plasmids
The packaging construct pCMgpRRE17, derived from
multiple fragments, was assembled in a series of sub-
cloning steps. pCMMTV molecular clone that was used
as a base for construction of the packaging construct
was described elsewhere [9]. Due to a delayed processing
of the Gag-Pro-Pol polyprotein, the gag-pro-pol-coding
region in the pCMMTV was replaced with the corre-
sponding region from a Mtv-1/MMTV(C3H) hybrid mo-
lecular clone [6]. The Mtv-1/MMTV(C3H) fragment
was amplified using the hybrid molecular clone as a
template and primers 1321FHind 5′-AAA AAA AAG
CTT GCA ACA GTC CTA ACA TTC AC-3′and 6980R
5′-CTC CTC CGC TTC GGA GAT-3′(HindIII in
italics), digested with HindIII (second HindIII site is in
pol) and cloned into the 9.1 kb HinIII-HindIII backbone
from pCMMTV. The resulting chimera pCMMTV1/2
was digested with XcmI and RsrII and ligated with the
2.1 kb XcmI-RsrII fragment obtained from pCMVrem
(a Rem expression plasmid constructed by inserting the
rem ORF into pcDNA3). The intermediate, env-3′LTR
lacking, product (pCM1/2envΔ) was then processed using
MluI and BstEII to delete the packaging signal (pCM1/
2envΔΨΔ). The digested vector was linked to a PCR prod-
uct amplified using primers CMVdelF 5′-ACA ACA AGG
CAA GGC TTG AC -3′and CMV3endR 5′-AAA AAG
GTG ACC GCT AGC AAT ATC GAT AAG CCA GTA
AG-3′ (BstEII in italics; MluI is downstream of CMVdelF)
and digested with the same restriction enzymes. In the
final cloning step the integrase (IN)-coding region from
the MMTV(GR) strain was substituted for the IN-coding
region present in the pCM1/2envΔΨΔ and the HIV-1
RRE region was inserted . The substitution was performed
as follows. The pCM1/2envΔΨΔ was cut with SnaBI and
BspTI and ligated with the 4.5 kb SnaBI-BspTI backbone
from an HIV-1-based packaging construct containing
the MMTV IN coding region in place of the HIV-1 IN
coding region (pLP1mIN). The pLP1mIN is derived
from pLP1 (Invitrogen). To replace the IN-coding regions,
the MMTV IN was amplified using primers CfHIV/
MMTV 5′-GGA ATC AGG AAA GTA CTA ACC GCTTTA GAG TCA GCT CA-3′and Dr 5′-AAA AAA CAC
CTG CTC CGG A TT AAG AAC CTC CTC CGC TTC
GGA GAT-3′(AccIII in italics). In a second PCR the
HIV-1 RT-coding region was amplified using primers
AfHIVpol 5′-GTT CCC TTA GAT AAA GAC TTC-3′
(EcoRV site is downstream of AfHIVpol)and BrMMTV/
HIV 5′-TGA GCT GAC TCT AAA GCG GTT AGT
ACT TTC CTG ATT CC-3′. The two PCR fragments
were fused using an overlap extension PCR strategy
with primers AfHIVpol and Dr. The fused product was
digested with EcoRV and AccIII and ligated with EcoRV/
AccIII-digested pLP1. The resulting packaging construct
was named pCMgpRRE17. To construct the vector, the
RSV U3 region amplified using RSVf_MluI (5′-TCG CGA
ACG CGTATG TAG TCT TAT GCA ATA CTC-3′; MluI
in italics) and RSVr (5′-GTG AAT GTT AGG ACT GTT
GCC GTT TAT TGT ATC GAG CTA G-3′) was fused to
the 1 kb R-U5-leader fragment derived from a molecular
clone pGR102 [18] (1321f: 5′-GCA ACA GTC CTA ACA
TTC AC-3′; 2041R: 5′-GCT TAG CCC TCA GC G AAT
TCG GTA CCG ATA TCA AGC TTC AAT TG C ATA
TGC TGT TCC CCT AGT C-3′; BbvCI and MfeI are
italics). The resulting overlap extension PCR product was
digested with MluI and BbvCI and ligated to the 6.9 kb
MluI-BbvCI fragment derived from the pCMMTV plasmid.
In the next step, a cytomegalovirus promoter-driven green
fluorescent protein (EGFP) expression cassette with the
postrtanscriptional regulatory elements from woodchuck
hepatitis virus (WPRE) and HIV-1 (RRE) (excised by MfeI/
EcoRI digestion from the 3rd generation lentiviral vector
RRL-cPPT-GFP [23]) was inserted to the intermediate vec-
tor digested with the same restriction enzymes. The result-
ing vector was named pRRpCeGFPWPRE25. To construct
SIN vectors, a long template PCR using the reverse primer
8750rKpnI (5′-AAA AAA GGT ACC CTA AGT GTA
GGA CAC TCT CGG-3′) in combination with either the
1218fKpnI (5′-AAA GCT AGC GGT ACC TCT GAT
CTG AGC TCT TAG TG-3′) or 1293fKpnI (5′-AAA
GCT AGC GGT ACC AAA GAG TGC TGA TTT TTT
GAG-3′) (KpnI in italics) forward primer and the vector as
a template was performed (Expand Long Template PCRR
System; Roche). The PCR product was digested with KpnI
and religated. This resulted in SIN vectors, pRRpCeGF
PWPRE25_1218 and pRRpCeGFPWPRE25_1293 having a
short (nt8750–nt9779) and long (nt8750–nt9866) deletion
in the 3′LTR, respectively (nt coordinates are according
to GenBank # M15122). All amplifications, unless stated
otherwise, were performed using Phusion High Fidelity
polymerase (New England Biolabs).
Downmodulation of gene expression
For gene knockdown, cells were seeded at a density of
2 × 105 cells/well (6 well plate and transfected using
DharmaFECT (Thermo Scientific) with 25 nM siRNA
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tive control a non-targeting control siRNA (siCON-
TROL Non-Targeting siRNA #2, Thermo Scientific) was
used. After 48 h of siRNA-mediated gene knockdown
the medium was removed and viral vectors at an MOI
of 0.1 in 0.6 ml DMEM with 10% FCS and 8 μg/ml of
polybrene (Sigma) were added. The EGFP-positive cells
were counted 72 h later by flow cytometry.
Flow cytometry
Transduced cells were inspected by fluorescence mi-
croscopy and transduction efficiency was analysed by
fluorescence-activated cell sorter (FACS with 488 nm
argon-ion laser fluorescence excitation source) analysis
and CellQuest software (50 000 events; FACSCalibur,
BD Biosciences). The cells were harvested, washed with
PBS and resuspended in PBS containing 0.5% FCS. Dead
cells and debris were excluded from analysis using forward
scatter (FSC) vs side scatter (SSC) plot. EGFP-expressing
cells were identified by the shift of fluorescence intensity
in the FL-1 channel. For antibody staining of hematopoietic
stem cells, the cell preparations were resuspended in
PBS containing 0.5% BSA and 2 mM EDTA (PBE) and
incubated with anti-CD34 (human cells) or anti-CD117
(murine cells) antibody (both Miltenyi Biotech) conju-
gated with phycoerythrin (PE) for 10 min. Following
washing in PBE, the cells were analyzed by FACS. Shift
of fluorescence intensity in the FL-2 channel was used
for quantification of PE positive cells.
For cell cycle analysis, γ-irradiated and non-irradiated
cells were stained with propidium iodide (PI) as de-
scribed in [49]. Briefly, cells were harvested by trypsi-
nization, collected by centrifugation (200 × g, room
temperature, 6 min) and resuspended at a density of
2 × 106 cells per ml of PBS. 0.5 ml of cellular suspen-
sion was transferred drop-wise to 4.5 ml of cold etha-
nol (70%) and incubated overnight on ice. Following
centrifugation, the cells were resuspended in PI-staining
solution consisting of PBS with 0.1% Triton ×-100, 0.2 g/l
DNase-free RNase A and 20 mg/l PI (15 min, 37°C) and
analyzed by flow cytometry. Cellular debris and aggregates
were excluded from analysis using pulse-width/pulse-area
signal (FL2-W vs. FL2-A) and DNA content of single cells
was determined (FL2-A vs. counts).
Detection and mapping of integration sites
Integration sites were recovered as described previously
with modifications [12]. Genomic DNA was purified,
digested with MseI (37°C, overnight) and ligated to MseI
linker (16°C, overnight). Seminested PCR was then
performed as decribed previously [50]. PCR products,
smaller than the internal control product (437 bp), were
gel excised, purified and sequenced on a Genome
Sequencer FLX + Titanum (Roche 454 Life Sciences).The obtained reads contained the vector and linker se-
quences as well as unknown human sequences. The
MMTV vector sequences were terminated by the canon-
ical CA dinucleotide, whereas the MMTV(SIN) vector
sequences were, due to an aberrant termination of tran-
scription, often terminated before or after the CA di-
nucleotide at the end of the 3′LTR. These sequences were
not derived from non-integrated proviral or plasmid DNA
contaminations as we have not detected the 5′LTR virus
fused to human genome DNA. Redundant 454 sequencing
reads were removed, aligned with the pRRpCeGFPW
PRE25_1218 and manually trimmed. Only sequences that
matched the human genome within five base pairs after
pRRpCeGFPWPRE25_1218 sequence and showed 95% or
greater identity to the human genome were considered as
true integration sites. Mapping to the human genome
(hg18) was performed using BLAT (UCSC Genome Bio-
informatics) [51]. The coordinates of RefSeq genes and
other genomic features were downloaded from the UCSC
Table Browser. The Cancer Genome Atlas (TCGA) (http://
cbio.mskcc.org/tcga-generanker/sources.jsp) and Tumor
Associated Gene database [52] were used to identify
cancer-relevant genes hosting vector integration sites. A
Galaxy platform, PERL and Visual Basic scripts were
used for comparisons of localizations of integration sites
with various chromosomal features [53]. HIV-1 (n = 3246)
and MLV (n = 885) integration sites were processed as
above for comparison (CL528773–CL529767; BH609398–
BH609877; CL799519–CL800849; AY516894.1–AY5174
69.1; AY515855–AY516880) [12,13,39]. The distribution
of vector integration sites was compared to a set of
100,000 random integration coordinates generated by
computer. Random coordinates that mapped to un-
annotated human genome sequences were removed
from the random dataset. Statistical significance of dif-
ferences in distribution of integration sites was deter-
mined using χ2 test. P values < 0.05 were considered
significant. Sequences were submitted to NCBI.
RNA extraction and RT-PCR
RNA was extracted from transduced cells using RNeasy
Mini kit (Qiagen), resuspended in nuclease free water
and treated with Turbo DNase (Ambion). The DNA-free
RNA was reverse transcribed into cDNA using SuperScript
III First-Strand Synthesis System and random primers,
following the manufacturer’s instructions (Invitrogen).
A semi-quantitative PCR (Platinum Taq; Invitrogen)
was then performed using the primers 1321 F (5′-GCA
ACA GTC CTA ACA TTC AC-3′) and 1637R (5′-CCC
AGT TCC AAT GGC TCA CCG TAA-3′) under the
following cycling conditions: initial denaturation at
94°C for 2 min followed by 25 cycles of 94°C for 15 s,
55°C for 30s and 72°C for 40 s and a final extension at
72°C for 7 min. Equivalent loading the quality of extracted
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(5′-ACA ACG AAT TTG GCT ACA GCA ACA-3′) and
GAPDHr (5′-GGT TGA GCA CAG GGT ACT TTA-3′)
under the same cycling conditions.
Western blot analysis
Whole-cell extracts were prepared by cell lysis, equiva-
lent protein content (20 μg; measured using DC Protein
Assay; Bio-Rad) boiled in SDS sample buffer, resolved on
SDS/PAGE, transferred onto a Hybond-P PVDF mem-
brane (GE Healthcare) and probed with anti-TNPO3
antibody (ab54353; Abcam) followed by secondary anti-
body conjugated with horse radish peroxidase (DAKO).
Equivalent protein loading was demonstrated using anti-
actin antibody (A2066; Sigma).
Additional files
Additional file 1: Figure S1. Mean fluorescence intensity of cells
transduced with retroviral vectors. The cells were analyzed by flow
cytometry 3 days post transduction. The mean values ± SD from three
experiments are shown. Figure S2. (A) Infectious titers of the MMTV(SIN)
vectors (black columns) relative to the non-SIN vector (white columns).
(B) Comparison of the mean fluorescence intensities (MFI) of SIN (black
columns) and non-SIN vectors (white columns). The mean values ± SD
from three experiments are shown. Figure S3. Transcription from MMTV
(pRRpCeGFPWPRE25) and MMTV(SIN) (pRRpCeGFPWPRE25_1218) provirus.
HeLa cells were transduced with either MMTV or MMTV(SIN) vectors and
cultured for two weeks. 24 h prior to RNA extraction the cells were stimulated
with dexamethasone (DEX+) or mock stimulated (DEX-). Extracted RNA was
treated with DNAseI and subjected to reverse transcription followed by PCR
with the MMTV-specific primers. Control experiments, in which the RT step
was omitted (RT-), served as controls for the genomic DNA contamination.
The same cDNA preparations were used for amplification of the GAPDH
mRNA. As a positive control 100 pg of plasmid DNA (pGR102; [18]) was used.
Mock: mock transduced cells; NTC: no template control. Figure S4. Ex vivo
transduction of hematopoietic lineage negative (Lin−) cells derived from
murine bone marrow. Bone marrow cells were enriched for the population
of Lin− cells using the Lineage Cell Depletion kit (Miltenyi Biotech). The
enriched cells were analysed by FACS using anti-CD117-PE antibody
(Miltenyi Biotech)(upper panel). The cells were cultured overnight in the
StemSpan medium either containing or lacking a murine cytokine cocktail
consisting of 100 ng/ml rmSCF, 100 ng/ml rmTPO, 100 ng/ml rmFlt3-L and
20 ng/ml IL3. Following the 16 h pre-incubation period, the cells (1 × 106
cells/ml) were transduced with MMTV-or HIV-1-based vectors (1.8 × 107 TU/
ml). 24 h after transduction, the vector-containing supernatant was replaced
with StemSpan medium with or without the murine cytokines. Five days
after transduction the cytokine-containing medium was added to cells
and they were cultured for 10 days. FACS analysis was used to detect
the expression of EGFP in the Lin− cells.
Additional file 2: Figure S5. Comparison of integration site distribution
within genes, tumor associated genes, CpG islands and open chromatin
regions. Nucleotide coordinates for the genomic features were obtained
from the USCS Genome Bioinformatics Table Browser using NCBI36/hg18
assembly of the human genome. For the tumor associated genes, The
Cancer Gene Atlas (TCGA) Gene Ranker and Tumor Associated Gene Database
(NCKU Bioinformatics center) were used to obtain a list of genes. A Chi-square
test was used to test differences between random dataset and vectors.
Figure S6. Comparison of integration site distribution within or near
(simple repeats: ± 1 kb; tRNA and miRNA: ± 10 kb) various genomic
features. Nucleotide coordinates and statistical evaluation of differences
was performed us described above. The GC content in a 100 nt window
surrounding the integration sites was computed and the frequency of
integrations in the loci with GC content exceeding 41% (average GCcontent for the human genome) was plotted for vectors and random
dataset. Figure S7. Gene density around integration sites. RefSeq genes
found in the vicinity (1 Mb window) of integration sites were counted.
The average and mean number of genes for vectors and random sites
are shown. The middle plots show the frequency of integrations in the
regions with a gene density of 0-10 genes, 11-20 genes and >20 genes
within the 1 Mb window. A Chi-square test was used to test differences
between random dataset and vectors. Bottom plots are histograms
displaying the distribution of integration sites relative to gene density
within a 1 Mb window surrounding integration sites.
Additional file 3: Table S1. Vector integration sites within the
tumor-associated genes (NCKU Bioinformatics Center). Integrants
within the tumor-associated genes are shown. The cell color indicates
whether a single or multiple integration events were detected within
genes. A single integration within a gene is shown uncolored (name
of integrant, position, strand). Two integration events of the same
vector in the same gene are in yellow. Two integrations of different
vectors are in orange. Red color indicates three different vectors found
within the same gene.
Additional file 4: Table S2. Vector integrations and the tumor
associated genes listed in The Cancer Gene Atlas. The same color coding
as above was used.
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